Plasmacytoid dendritic cells in patients with autoimmune thyroid disease

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages 2822-2833

  Leskela, Susanna ^a   Rodríguez Muñoz, Ana ^a   De La Fuente, Hortensia ^a,b   Figueroa Vega, Nicté ^a   Bonay, Pedro ^c   Martín, Pilar ^b   Serrano, Ana ^a   Sánchez Madrid, Francisco ^a,b   González Amaro, Roberto ^d   Marazuela, Mónica ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD69 ANTIGEN; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN LIKE TRANSCRIPT 1; IMMUNOGLOBULIN LIKE TRANSCRIPT 3; IMMUNOGLOBULIN LIKE TRANSCRIPT 4; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; P SELECTIN GLYCOPROTEIN LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; ANALYTICAL PARAMETERS; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE THYROIDITIS; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENDOCRINE OPHTHALMOPATHY; FEMALE; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IN VITRO STUDY; KYNURENINE TRYPTOPHAN RATIO; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE ACTIVATION; THYROID FUNCTION;

ADULT; AUTOANTIBODIES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FEMALE; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THYROID FUNCTION TESTS; THYROID GLAND; TRYPTOPHAN;

EID: 84879900690     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1273     Document Type: Article

References (40)

1. Benvenga S, Trimarchi F. Changed presentation of Hashimoto's thyroiditis in North-Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid. 2008;18:429-441. (Pubitemid 351519545)
2. Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. Curr Opin Rheumatol. 2007;19:44-48. (Pubitemid 44885726)
3. Devendra D, Eisenbarth GS. 17. Immunologic endocrine disorders. J Allergy Clin Immunol. 2003;111:S624-S636. (Pubitemid 36223300)
4. Lipscomb MF, Masten BJ. Dendritic cells: immune regulators in health and disease. Physiol Rev. 2002;82:97-130. (Pubitemid 34654216)
5. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151-161. (Pubitemid 37336516)
6. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111-165.
7. Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. Immunol Rev. 2010;234:317-334.
8. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234:142-162.
9. Urzainqui A, Martínez del Hoyo G, Lamana A, et al. Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J Immunol. 2007;179:7457-7465.
10. Chang CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol. 2002;3:237-243. (Pubitemid 34218114)
11. Colonna M, Navarro F, Bellón T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997;186:1809-1818. (Pubitemid 27524591)
12. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-268. (Pubitemid 33706004)
13. Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001;193:839-846.
14. Sancho D, Gómez M, Viedma F, et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J Clin Invest. 2003;112:872-882. (Pubitemid 38063745)
15. Lamana A, Martin P, de la Fuente H, et al. CD69 modulates sphingosine-1-phosphate-induced migration of skin dendritic cells. J Invest Dermatol. 2011;131:1503-1512.
16. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297:1867-1870. (Pubitemid 35024345)
17. Fallarino F, Grohmann U, Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol. 2012;42:1932-1937.
18. Puccetti P, Fallarino F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. Blood Cells Mol Dis. 2008;40:101-105. (Pubitemid 350192308)
19. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008;181:5396-5404.
20. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957. (Pubitemid 47300009)
21. Marazuela M, Garcia-López MA, Figueroa-Vega N, et al. Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab. 2006;91:3639-3646. (Pubitemid 44402149)
22. Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J Immunol. 2005;174:7433-7439. (Pubitemid 40705715)
23. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol. 2003;170:1304-1312. (Pubitemid 36139497)
24. Horwitz DA, Zheng SG, Gray JD. Natural and TGF-β-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008;29:429-435.
25. Mao C, Wang S, Xiao Y, et al. Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol. 2011; 186:4734-4743.
26. Bartalena L, Baldeschi L, Dickinson A, et al for the European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-285. (Pubitemid 351404990)
27. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9-14. (Pubitemid 27313981)
28. Figueroa-Vega N, Sanz-Cameno P, Moreno-Otero R, Sanchez-Madrid F, Gonzalez-Amaro R, Marazuela M. Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J Clin Endocrinol Metab. 2009;13:13.
29. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50:1861-1872. (Pubitemid 38725099)
30. Rönnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci. 2011;116:227-237.
31. Van Vré EA, Van Brussel I, de Beeck KO, et al. Changes in blood dendritic cell counts in relation to type of coronary artery disease and brachial endothelial cell function. Coron Artery Dis. 2010;21:87-96.
32. Grimaldi D, Louis S, Pène F, et al. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med. 2011;37:1438-1446.
33. Baumgart DC, Metzke D, Guckelberger O, et al. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol. 2011; 166:46-54.
34. Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB, Tak PP. Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profiles. Am J Pathol. 2008;172:940-950. (Pubitemid 351519991)
35. Wollenberg A, Wagner M, Günther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol. 2002;119:1096-1102. (Pubitemid 35434173)
36. Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol. 2007;179:5204-5210.
37. Eloranta ML, Franck-Larsson K, Lövgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis. 2010;69:1396-1402.
38. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008;38:2024-2033.
39. Kuang M, Wang S, Wu M, Ning G, Yao Z, Li L. Expression of IFNα-inducible genes and modulation of HLA-DR and thyroid stimulating hormone receptors in Graves' disease. Mol Cell Endocrinol. 2010;319:23-29.
40. Ruiz-Riol M, Barnils Mdel P, Colobran Oriol R, et al. Analysis of the cumulative changes in Graves' disease thyroid glands points to IFN signature, plasmacytoid DCs and alternatively activated macrophages as chronicity determining factors. J Autoimmun. 2011;36: 189-200.